NEW YORK (GenomeWeb News) – Courtagen Life Sciences today said that Alliance Global Group will distribute the firm's molecular diagnostic tests in certain emerging markets.
Dubai-based Alliance Global sells biomedical products in the Middle East, Africa, and Asia. It will have exclusive rights to distribute a number of Courtagen tests for genetically based disorders. Thus far, the Woburn, Mass.-based firm offers tests for mitochondrial disorders and a new panel for epilepsy and seizure. Courtagen also plans to develop tests for other neurological disorders.
Financial and other terms of the agreement were not disclosed.
Courtagen runs a CLIA lab that develops sequencing-based tests and uses the firm's proprietary bioinformatics platform called ZiPhyr.
Brian McKernan, CEO of Courtagen, said in a statement that the pact with Alliance Global "is a critical component of Courtagen's international business expansion."